Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin

·
Citation
PDF, XML
Authors

Abstract

The 3D-structure of the major surface viral antigen from the recent H1N1 pandemic influenza virus (A/Darwin/2001/2009) was determined to 2.8 Å resolution. The structure was used to analyze changes in the HA that have emerged during the first 11 months of the pandemic and have raised public health concerns. Receptor binding properties of this protein reveals a strict preference for human-type receptors.

Funding Statement

Research was funded by the Centers for Disease Control and Prevention.

Introduction

The first influenza pandemic of the new century emerged in April 2009, when a new H1N1 influenza virus (H1N1pdm), found in patients in Mexico and the United States, spread rapidly across the world by human-to-human transmission, resulting in the World Health Organization declaring a global pandemic on June 11 th 2009 [1]. The pandemic H1N1 virus (2009 H1N1) was unique in that it had a gene constellation from both North American and Eurasian swine lineages that had not been isolated previously in either swine or human populations [2]. Phylogenetic and antigenic analysis of the hemagglutinin (HA) gene revealed it to be distinct from seasonal human H1N1 viruses but more similar to the classical North American swine lineage.

Ten months after the first viruses were isolated, the virus is still antigenically homogeneous [3]. However, as the HA continues to circulate in the human population, its HA antigenic sites will continue to be targeted by antibody-mediated selection pressure. Therefore it is important from a public health perspective to structurally characterize the hemagglutinin so that the research community has a template with which to visualize any changes affecting antigenicity or virulence that may emerge as this virus evolves. To this end, we have cloned, expressed and solved the structure of a pandemic H1 hemagglutinin by x-ray crystallography. The structure was used to analyze amino acid substitutions in the HA that have raised some concern during the last 11 months of global surveillance activities. The same protein was analyzed by glycan microarray and compared to seasonal and other pandemic variants. Results reveal a strict human-like receptor specificity.

Materials and Methods

Recombinant HA cloning and expression: Utilizing a similar cloning strategy from previous studies [4][5][6], the HA ectodomain of the 2009 H1N1 pandemic influenza virus, A/Texas/05/2009 (Accession: FJ966959) was codon optimized, synthesized and cloned into the baculovirus transfer vector, pAcGP67-A (BD Biosciences, San Jose, CA) by Geneart AG, Germany. Constructs containing Ohio/7/2009 (Accession: FJ969535), A/Utah/20/2009 (Gisaid Accession: EPI217204) and A/Darwin/2001/2009 (Accession: GQ243757) were generated by mutagenesis of the A/Texas/05/2009 clone (A/Ohio/7/2009:Ser203Thr/Val411Ile; A/Darwin2001/2009:Ser203Thr/Arg205Lys/Val411Ile; A/Utah/20/2009:Asn156Asp/Gln293His) using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene, CA). Seasonal H1N1 HA constructs were cloned into the baculovirus transfer vector, pAcGP67-A (BD Biosciences, San Jose, CA). Transfection and virus amplification were carried out as described previously [4][5][6]. Protein expressed from Trichoplusia ni (Hi5) cells (Invitrogen, Carlsbad, CA) in 10-stack CellSTACK™ culture chambers (Corning Inc., Corning, NY) was recovered from the culture supernatant and purified by metal affinity chromatography, subjected to thrombin cleavage and gel filtration chromatography [7]. Purified monomeric protein was buffer exchanged into 10 mM Tris-HCl, 50 mM NaCl, pH 8.0 and concentrated to 7.8 mg/ml for crystallization trials. At this stage, the protein sample still contained the additional plasmid-encoded residues at both the N (ADPG) and C terminus (SGRLVPR).

Crystallization and data collection: Initial crystallization trials were set up using a TopazTM Free Interface Diffusion (FID) Crystallizer system (Fluidigm Corporation, San Francisco, CA). Crystals were observed in conditions containing various molecular weights of PEG polymer. Following optimization, diffraction quality crystals for Darwin09 were obtained at 20 ºC using a modified method for ‘microbath under oil’ [8], by mixing the protein with reservoir solution containing 22% PEG2000MME, 0.1M HEPES at pH 7.5. Crystals were flash-cooled at 100K, data was collected at the Advanced Photon Source (APS) beamline 22-BM at 100K and processed with the DENZO-SACLEPACK suite [9]. The data were indexed in spacegroup P1 with unit cell dimensions a=73.98Å, b=109.71Å, c=129.90Å; α=86.25°, β=74.68°, ϒ=75.10°. Statistics for data collection are presented in Table 1.

Structure determination and refinement: The structure of Darwin09 was determined by molecular replacement with Phaser [10] using the HA structure from A/Japan/305/1957, pdb:3KU3 [11] (HA1, 55% identity; HA2, 82% identity) as the search model. Six hemagglutinin monomers making one non-crystallographic trimer, related by a non-crystallographic 3-fold and three monomers that form one-third and two-thirds of two crystallographic trimers, occupy the asymmetric unit with an estimated solvent content of 55% based on a Matthews’ coefficient (Vm) of 2.75 Å 3/Da. Rigid body refinement of the trimer led to an overall R/Rfree of 48.1%/48.6 %. The model was then “mutated” to the correct sequence and rebuilt by Coot [12], then the protein structures were refined with REFMAC [13] using TLS refinement [14]. The final models were assessed using MolProbity [15]. Statistics for data processing and refinement are presented in Table 1.

Table 1:Data collection and refinement statistics.

Data collection Darwin09
Space group P1
Cell dimensions a=73.98Å, b=109.71Å, c=129.90Åα=86.25°, β=74.68°, ϒ=75.10°
Resolution (Å) 50-2.8 (2.90-2.80)*
R sym 7.6 (44.2)
<I/σ> 9.7 (1.6)
Completeness (%) 98.1 (95.7)
Redundancy 2.0 (1.9)
Refinement
Resolution (Å) 50-2.8 (2.87-2.80)
No. of reflections (total) 87344
No. of reflections (test) 4608
R work / R free 23.1/25.6
No. of atoms 23552
r.m.s.d.- bond length (Å) 0.016

r.m.s.d.- bond angle (°)

1.701
MolProbity # scores
Favored (%) 95.3
Allowed (%) 99.7
Outliers (%) (No. of residues) 0.3 (9/2934)

* Numbers in parentheses refer to the highest resolution shell.

# Reference [15]

Glycan microarray analysis: Microarray printing and recombinant HA analyses have been described previously [6][16]. Imprinted slides produced specifically for influenza research for the CDC using the CFG glycan library (CDC version 1 slides; see Table 2 for glycans used in these experiments) were used.

Table 2: Glycans covalently attached on the glycan microarray . Different categories of glycans on the array are color-coded in column 1 as follows: No color, sialic acid; blue, α2-3 sialosides; red, α2-6 sialosides, violet, mixed α2-3/ α2-6 biantennaries; green, N-glycolylneuraminic acid-containing glycans; brown, α2-8 linked sialosides; pink, b2-6 linked as well as 9-O-acetylated sialic acids; grey, asialo glycans.

Chart # Structure Description
1 α-Neu5Ac α-Neu5Ac
2 α-Neu5Ac α-Neu5Ac
3 b-Neu5Ac β-Neu5Ac
4 Neu5Acα2-3(6-O-Su)Galβ1-4(Fucα1-3)GlcNAcβ α2-3 so4
5 Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα α2-3 so4
6 Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ α2-3 so4
7 Neu5Acα2-3Galβ1-4(Fucα1-3)(6OSO3)GlcNAcβ α2-3 so4
8 Neu5Acα2-3Galβ1-3(6OSO3)GlcNAc α2-3 so4
9 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ di-sialoside
10 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1-6)GalNAcβ di-sialoside
11 Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-3 biantennary
12 Neu5Acα2-3Galβ α2-3
13 Neu5Acα2-3GalNAcα α2-3
14 Neu5Acα2-3Galβ1-3GalNAcα α2-3
15 Neu5Acα2-3Galβ1-3GlcNAcβ α2-3
16 Neu5Acα2-3Galβ1-3GlcNAcβ α2-3
17 Neu5Acα2-3Galβ1-4Glcβ α2-3
18 Neu5Acα2-3Galβ1-4Glcβ α2-3
19 Neu5Acα2-3Galβ1-4GlcNAcβ α2-3
20 Neu5Acα2-3Galβ1-4GlcNAcβ α2-3
21 Neu5Acα2-3GalNAcβ1-4GlcNAcβ α2-3
22 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ α2-3
23 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ α2-3
24 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ α2-3
25 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ α2-3
26 Neu5Acα2-3Galβ1-3GalNAcα α2-3
27 Galβ1-3(Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-6)GalNAcβ α2-3 fucosylated
28 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ α2-3 fucosylated
29 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ α2-3 fucosylated
30 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ α2-3 fucosylated
31 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ α2-3 fucosylated
32 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ α2-3 fucosylated
33 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1­3Galβ1-4(Fucα1-3)GlcNAcβ α2-3 fucosylated
34 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc α2-3 fucosylated
35 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ α2-3 internal
36 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ α2-3 internal
37 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ α2-3 internal
38 Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ α2-3 internal
39 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ α2-3 internal
40 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ α2-3 internal
41 Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ α2-6 so4
42 Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1­6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 branched
43 GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1­4GlcNAcβ1-4GlcNAcβ α2-6 branched
44 Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1­6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 branched
45 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1­4GlcNAcβ1-4GlcNAcβ α2-6 branched
46 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 biantenary
47 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 biantenary
48 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 biantenary
49 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1­6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-6 biantenary
50 Neu5Acα2-6GalNAcα α2-6
51 Neu5Acα2-6Galβ α2-6
52 Neu5Acα2-6Galβ1-4Glcβ α2-6
53 Neu5Acα2-6Galβ1-4GlcNAcβ α2-6
54 Neu5Acα2-6Galβ1-4GlcNAcβ α2-6
55 Neu5Acα2-6GalNAcβ1-4GlcNAcβ α2-6
56 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ α2-6
57 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1­4(Fucα1-3)GlcNAcβ α2-6 + fucosylation
58 Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glcβ α2-6 internal
59 Galβ1-3(Neu5Acα2-6)GalNAcα α2-6 internal
60 Neu5Acα2-3Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-3/6 biantennary
61 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-3Galβ1-4GlcNAcβ1­2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ α2-3/6 biantennary
62 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAc α2-3/6 disialoside
63 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα α2-3/6 disialoside
64 Neu5Acα2-3(Neu5Acα2-6)GalNAcα α2-3/6 disialoside
65 Neu5Gcα Neu5Gc α
66 Neu5Gcα2-3Galβ1-3(Fucα1-4)GlcNAcβ Neu5Gc α2-3
67 Neu5Gca2-3Galβ1-3GlcNAcβ Neu5Gc α2-3
68 Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ Neu5Gc α2-3
69 Neu5Gcα2-3Galβ1-4GlcNAcβ Neu5Gc α2-3
70 Neu5Gcα2-3Galβ1-4Glcβ Neu5Gc α2-3
71 Neu5Gcα2-6GalNAcα Neu5Gc α2-6
72 Neu5Gcα2-6Galβ1-4GlcNAcβ Neu5Gc α2-6
73 Neu5Acα2-8Neu5Acα Neu5Ac α2-8
74 Neu5Acα2-8Neu5Acα2-8Neu5Acα Neu5Ac α2-8
75 Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ Neu5Ac α2-8 α2-3
76 Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ Neu5Ac α2-8 α2-3
77 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ Neu5Ac α2-8 α2-8 α2-3
78 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ Neu5Ac α2-8 α2-8 α2-3
79 Neu5Acα2-8Neu5Acα Neu5Ac α2-8
80 Neu5Acα2-8Neu5Acβ Neu5Ac α2-8
81 Neu5Acα2-8Neu5Acα2-8Neu5Acβ Neu5Ac α2-8 α2-8
82 Neu5Acβ2-6GalNAcα β2-6
83 Neu5Acβ2-6Galβ1-4GlcNAcβ β2-6
84 Neu5Gcβ2-6Galβ1-4GlcNAc β2-6
85 Galβ1-3(Neu5Acβ2-6)GalNAcα β2-6
86 9NAcNeu5Aca 9NAcNeu5
87 9NAcNeu5Acα2-6Galβ1-4GlcNAcβ 9NAcNeu5
88 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ asialo
89 Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ asialo
90 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ asialo
91 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ asialo
92 GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ asialo
93 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ asialo
94 Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ asialo
95 Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ asialo
96 Galβ1-3GalNAc asialo

Key:

Neu5Ac = Sialic acid

Neu5Gc = N-glycolylneuraminic acid

OSO3= sulfate; Gal = galactose

Fuc = fucose

GlcNAc = N-Acetyl-D-glucosamine

GalNAc = N-acetyl-D-galactosamine

Glc = D-glucose

Man = D-mannose

9NAc = 9-O-acetyl

Results and Discussion

Expression and purification Recombinant HA protein from A/Darwin/2001/2009 (H1N1) (Darwin09) virus was expressed in a baculovirus expression system utilizing a thrombin site at the C-terminus of Darwin09 followed by a trimerizing sequence (foldon) from the bacteriophage T4 fibritin for generating functional trimers [17], and a His-Tag to aid purification. Although protein was expressed as a trimer, only monomers were purified by gel filtration after foldon removal by the thrombin cleavage step. However, these monomers were stable, the protein stock maintained its monomeric state even after 8 weeks storage at 4 °C (confirmed by dynamic light scattering analysis). However, monomers were still able to reform trimers in the crystal as evidenced by the structure reported here.

Fig. 1: Structural overview of the Darwin09 HA monomer.

(A) One monomer is shown with the location of the receptor-binding site (RBS) and the HA1/HA2 cleavage site circled. The positions of residues discussed in the text are highlighted in red (B) H1 HA antigenic sites, Ca, Cb, Sa and Sb are mapped onto a surface representation of the HA1 domain of the Darwin trimer with positions of nearby potential glycosylation sites colored orange. (C) For comparison, a model of the last H1N1 seasonal vaccine component, A/Brisbane/59/2009 was generated by homology modeling [18]. (D) RBS of Darwin09 with the three structural elements comprising this binding site, the 130-loop, 220-loop and the 190-helix, colored light blue, light green and olive, respectively. All the figures were generated and rendered with the use of MacPyMOL [19].


Overall StructureBy using x-ray crystallography, the structure of pandemic H1N1 HA from the Darwin09 virus was determined to 2.8 Å resolution (Table 1). The overall structure of Darwin09 is similar to other reported HA structures with a globular head containing the RBS and vestigial esterase domain, and a membrane proximal domain with its distinctive, central helical stalk and HA1/HA2 cleavage site (Figure 1A). We selected representative HAs from human pandemic subtypes for structural analysis. Darwin09 HA was found to be structurally very similar to the 1918-pandemic HA and the pandemic potential H5N1 HA in comparisons. Although closely related to the HA2 domains of the other swine H1, H2 and H3 subtypes in the analysis, the HA1 domains were more divergent (Table 3).

Table 3: Comparison of r.m.s.d. (Å) for HA1 and HA2 domains. For analyzing differences in the overall structure, r.m.s.d. values were calculated between monomers or domains of different pandemic and pandemic potential HA’s, after the Ca atoms of the HA2 domains were superposed by sequence and structural alignment onto the equivalent domains of Darwin09.

Subtype PDB entry HA1 Domain HA2 Domain
1918-Hu-H1N1 South Carolina/1/18 1RD8 0.57 1.10
1930-Swine-H1N1 A/swine/Iowa/30, 1RUY 2.38 1.33
1957-Hu-H2N2 A/Japan/305/57 3KU5 3.23 1.76
1968-Hu-H3N2 A/Hong Kong/1/68 2HMG 7.08 1.86
2004-Hu-H5N1 A/Vietnam/1203/04 2FK0 1.52 0.88

Although six asparagine-linked glycosylation sequons are present in the Darwin09 HA monomer, interpretable electron density was observed at only 3 sites in HA1, Asn23, Asn87 and Asn276. At these sites, only one or two N-acetyl glucosamines could be interpreted. Compared to recent seasonal HAs, potential glycosylation sites in the HA1 of the pandemic HA are in comparable positions (Figure 1B and C). Position 87 in the pandemic HA is also a glycosylation site in seasonal HAs and has been a conserved feature since 1918 [7]. On recent H1 HAs, a second site, at Asn54, is in very close proximity to Asn87 and it is not known whether both sites are occupied. Similarly, the pandemic HA also has two potential glycosylation sites at positions 276 and 286, at the bottom of the HA1 that are close together. However, no conclusions can be made from this structure with respect to double occupancy at these positions since density was only observed at position 276 in two of the six chains in the asymmetric unit.

The receptor binding domainThe receptor-binding site (RBS) is at the membrane distal end of each HA monomer and its specificity for sialic acid and the nature of its linkage to a vicinal galactose residue determines host range-restriction. As for other HA structures, the Darwin09 RBS is composed of three structural elements: a 190-helix (residues 184-191), a 220-loop (residues 218-225), and a 130-loop (residues 131-135), while other highly conserved residues: Tyr91, Trp150, His180, and Tyr192 form the base of the pocket (Figure 1D).

Interestingly, previous published research highlighted dual receptor specificity for the early pandemic viruses [20]. Using carbohydrate microarray analysis, the authors observed mixed a2-3/ α2-6 receptor specificity with two pandemic viruses (California/4/2009 and Hamburg/5/2009), while a seasonal H1N1 virus bound exclusively to α2-6-linked sialosides. Using recombinant HA we can also probe these microarray platforms [4][5][6]. By pre-complexing trimers using primary and secondary antibodies one can overcome the low affinity of HA for its glycan ligand [21] by increasing the valency. Results using recombinant HA revealed a strict preference for five human-type sialyl-glycans, with no significant binding to avian α2-3 receptor analogs. All pandemic recombinant HAs bound to a α2-6 sialylated tri-N-acetyllactosamine glycan in which the two proximal (reducing end) lactosamines are α1-3 fucosylated (glycan #57 in the Table 2) as well as to a structurally related long linear α2-6 sialylated di-N-acetyllactosamine (Figure 2, glycan #56). These glycans were detected in N-glycans of cultured human bronchial epithelial cells [22]. Two other structurally diverse glycans, a α2-6 sialylated-sulfated N-acetyllactosamine structure (glycan #41) and the α2-6 sialylated LacNAc (glycans #53 & 54) were also recognized by these HAs. In addition, the proteins in this study bound weakly to α2-6 sialylated bi-antennary glycans (glycans #46-48), which are typically found on membrane glycoproteins [23]. These results were comparable to the two seasonal HAs used in the analysis (A/Solomon Islands/3/2006 and A/Brisbane/59/2007 are the two H1N1 components of the 2007-2008, 2008-2009 and 2009-2010 trivalent vaccine) although good binding to the α2-6 sialylated bi-antennary glycans (glycans #46-48) was observed for the Solomon Islands/3/2006 recombinant HA. Thus, these pandemic viruses bind to human type receptors as shown and postulated by previous reports [24][25]. This strict specificity is in contrast to the Childs et al report [20]. However, these differences can be attributed to the different platforms used as well as increased valency of the virus, which might enhance binding to weak ligands.

Fig. 2: Glycan microarray analysis of pandemic H1 recombinant HAs.

Protein of A/Texas/5/2009, A/Darwin/2001/2009, A/Ohio/7/2009 and A/Utah/20/2009 were analyzed and compared to the recent vaccine candidates from seasonal H1 HAs, A/Solomon Islands/3/2006 and A/Brisbane/59/2007. Colored bars highlight glycans that contain α2-3 SA (blue) and α2-6 SA (red), α2-6/ α2–3-mixed SA (purple), N-glycolyl SA (green), α2-8 SA (brown), b2-6 and 9-O-acetyl SA, and non-SA (grey). Error bars reflect the standard deviation in the signal for six independent replicates on the array. Structures of each of the numbered glycans are found in Table 2.


Genetic and antigenic changes Four antigenic sites for H1N1 virus HAs, have been identified (Ca, Cb, Sa, and Sb) [26][27]. In Darwin09, with the exception of Ca, all are exposed for antibody recognition. The Ca site is proximal to the oligosaccharide at HA1 Asn87, which may interfere with antibody recognition of this region. In recent seasonal H1 HAs the Sa site (and possibly Sb) looks to be affected by the presence of two glycosylation sites at positions 125 and 159 (Figure 1D). Lack of these sites in the pandemic HA exposes the entire top of the HA1 for targeting by the immune system and this feature may explain why the antibody recall response to the pandemic vaccine in adults was so effective [28].

Since the pandemic virus first emerged, the majority of viruses have shared a Ser203Thr amino acid change in the HA. This position is near the monomer-monomer interface and the small change in side chain appears not to have had a dramatic effect on the HA structure. Introduction of the extra methylene group in the side chain may help to stabilize the loop region in its surrounding environment (Figure 1A). Currently, two circulating subsets of viruses have amino acid changes, Asp222Glu or Glu374Lys, in the HA. The Asp222Glu mutation is in the receptor-binding site and may modulate which glycans bind to the receptor (Figure 1A). The latter mutation at position 374 is in the HA2 (residue 47) and points into the cavity where the fusion peptide resides in the mature fusion ready form of the HA molecule. Although this mutation may affect stability in this region (Figure 1A), it is also close to a region identified by two recent HA/neutralizing antibody structures which target the stem region of the HA [29][30]. Little is known about the immune response to this region and whether this mutation is able to modulate antibody binding.

Other HA mutations have also been observed that affect antigenicity, but most have been sporadic throughout the year, geographically separated or results of egg growth [31]. In particular, changes at positions 153-157 in the HA have been associated with reduced HI titers with ferret antisera to the A/California/7/09 vaccine virus. In most (if not all) cases, these changes have emerged after virus propagation in cell cultures. The structure highlights this region to be a prominent loop on the top left of the receptor binding site and is a component of the Sa (H1) or Site B (H3) antigenic site (Figure 1A and 1B) [27]. In the pandemic H1 HA, this region is exposed to the host immune system and not masked by vicinal glycosylation sites. Although this position is known to affect antigenicity, it does not appear to change receptor binding as shown by the glycan microarray results for A/Utah/20/2009 which has as Asn156Asp change compared to the other pandemic virus HAs analyzed (Figure 2). Its ability to change easily also highlights this region as a potential ‘hot spot’ for future mutation as the human population gains immunity and the virus experiences increased pressure to evade the immune response.

More recently, there has been focus on the possible role of a mutation at position 222 and its role in severe clinical outcome [32][33]. The Asp222Gly and Asp222Asn single and mixed variants have been found in pandemic viruses as well as direct sequencing from clinical specimens collected throughout the 2009 pandemic from approximately 20 countries, including Norway, Mexico, Ukraine and the USA. As already described above, position 222 resides in the receptor binding site of the HA protein and may possibly influence binding specificity. Indeed, the HA from the previous H1N1 pandemic in 1918 switched from avian to human receptor specificity through mutation at two positions (Glu187Asp and Gly222Asp) [5]. (The pandemic virus HA is also an Asp at position 187). In addition, the A/New York/1/18 strain of the 1918 pandemic possessed a Gly at position 222 and this markedly affected receptor binding, reducing α2-6 preference and increasing weak α2-3 [5].

Fig. 3: Glycan microarray analysis of A/Texas/5/2009 mutants.

The effect of position 222 mutations was assessed on the A/Texas/5/2009 framework by mutating the Asp to: A) a Gly and B) an Asn. Graphs are formatted as for Figure 2. C) The receptor binding site of Darwin09 with a 6’-sialyllactosamine (6’-SLN) modeled into the pocket highlights the residues that could contribute to the hydrogen bonding network between the receptor and the HA. Putative hydrogen bond interactions between the glycan and the HA RBS are shown as green broken lines.


To address this question on the 2009 pandemic H1N1 virus, we mutated position 222 on the A/Texas/5/2009 HA to produce variants with either an Asp222Gly or an Asp222Asn mutation. Interestingly, glycan microarray analysis of these mutants revealed a α2-6 binding profile (Figure 3A and 3B) similar to the wild-type A/Texas/5/2009 recombinant HA (Figure 2). However, these mutants also bound weakly to sulfated α2-3 sialylglycans (glycans #4-8) as well as α2-3 and α2-3/α2-6 di-sialoside structures (glycans #9 & 10). Currently, it is unknown if the same profile will be reflected with viruses carrying the same mutations on the glycan microarray or if the increased valency of the virus due to the increased number of HAs on the virus surface will enhance this weak binding. Thus, on the current pandemic HA framework, the effect of these mutations at position 222 on receptor binding appears less dramatic when compared to the 1918 framework since the binding preference for α2-6 sialylglycans is still maintained. Analysis of the RBS of Darwin09 offers a possible reason. The galactose of α2-6-linked receptors can interact via its 3- and 2-hydroxyls through a hydrogen bond network using residues Lys219, Asp222 and Glu224. A loss of Asp222 through mutation might not compromise this network to the same extent as was seen in the 1918 HA framework when the Asp225Gly mutation was introduced [5].

Conclusions

Although a number of mutations have been reported in circulating pandemic H1N1 viruses, they have not affected virus antigenicity and pathogenicity. The use of the Darwin09 structure to analyze the interactions of these HAs with virus receptors highlights the importance of having structural information to aid such analysis. The expression system used here also provides an important route for the safe production of these pandemic proteins on a large scale. Availability of recombinant protein enables its use for downstream applications such as glycan microarray analysis, as described here, reagents for diagnostic kit development or as antigens for antibody production. If this methodology were not available, HA production from the virus would have been difficult at the start of the pandemic, due to stringent biosafety requirements. Rapid determination and dissemination of the pandemic H1N1 hemagglutinin 3-D structure and characterization of its receptor specificity should enable the medical and public health research community to develop improved intervention approaches to control and prevent influenza morbidity and mortality as this virus becomes endemic in human populations.

Competing Interests

The authors have declared that no competing interests exist.

Acknowledgements

Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. The authors would like to thank the staff of SER-CAT sector 22 for their help with data collection and Ruben Donis (CDC) for help and advice during the project and preparation of this manuscript. The atomic coordinates and structure factors of the HA for Darwin/2001/2009 are available from the RCSB PDB under accession code 3M6S. Glycan microarray data presented here will be made available on-line through the Consortium for Functional Glycomics web site upon publication (www.functionalglycomics.org). The Glycan Microarray was produced for the Centers for Disease Control and Prevention using a glycan library generously provided by the Consortium for Functional Glycomics funded by National Institute of General Medical Sciences Grant GM62116. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry.

References

  • WHO (2009) World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/print.html
  • Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. (2009) Antigenic and genetic characteristics of swine-origin A(H1N1) influenza viruses circulating in humans. Science 325:197-201. Epub 2009 May 22. PubMed PMID: 19465683.
  • WHO (2010) Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. http://www.who.int/csr/disease/influenza/201002_Recommendation.pdf
  • Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, Wilson IA. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol. 2008 Sep 19;381(5):1382-94. Epub 2008 Apr 11. PubMed PMID: 18672252; PubMed Central PMCID: PMC2519951.
  • Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol. 2006 Feb 3;355(5):1143-55. Epub 2005 Nov 18. PubMed PMID: 16343533.
  • Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006 Apr 21;312(5772):404-10. Epub 2006 Mar 16. PubMed PMID: 16543414.
  • Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004 Mar 19;303(5665):1866-70. Epub 2004 Feb 5. PubMed PMID: 14764887.
  • Chayen NE, Shaw-Steward PD, Blow DM (1992) Microbatch crystallization under oil -- a new technique allowing many small volume crystallization experiments J Cryst Growth 122: 176-180.
  • Otwinowski A, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Meothds in Enzymology 276: 307-326.
  • McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005 Apr;61(Pt 4):458-64. Epub 2005 Mar 24. PubMed PMID: 15805601.
  • Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010 Feb;84(4):1715-21. Epub 2009 Dec 9. PubMed PMID: 20007271; PubMed Central PMCID: PMC2812380.
  • Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. Epub 2004 Nov 26. PubMed PMID: 15572765.
  • Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3. PubMed PMID: 15299374.
  • Winn MD, Isupov MN, Murshudov GN. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):122-33. PubMed PMID: 11134934.
  • Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, Richardson DC. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83. Epub 2007 Apr 22. PubMed PMID: 17452350; PubMed Central PMCID: PMC1933162.
  • Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, Razi N, Stevens DJ, Skehel JJ, van Die I, Burton DR, Wilson IA, Cummings R, Bovin N, Wong CH, Paulson JC. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17033-8. Epub 2004 Nov 24. PubMed PMID: 15563589; PubMed Central PMCID: PMC534418.
  • Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, Guo Y, Lustig A, Bächinger HP, Engel J. Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol. 2001 May 18;308(5):1081-9. PubMed PMID: 11352592.
  • Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003 Jul 1;31(13):3381-5. PubMed PMID: 12824332; PubMed Central PMCID: PMC168927.
  • Delano WL (2002) The Pymol Molecular Graphics System. http://wwwpymolorg
  • Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, Campanero-Rhodes MA, Zhang Y, Eickmann M, Kiso M, Hay A, Matrosovich M, Feizi T. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 2009 Sep;27(9):797-9. PubMed PMID: 19741625.
  • Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, Park SJ, Skehel JJ, Wiley DC. Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. Biochemistry. 1992 Oct 13;31(40):9609-21. PubMed PMID: 1327122.
  • Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey TM, Sasisekharan V, Sasisekharan R. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008 Jan;26(1):107-13. Epub 2008 Jan 6. PubMed PMID: 18176555.
  • Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007 May 9;4:42. PubMed PMID: 17490484; PubMed Central PMCID: PMC1876801.
  • Soundararajan V, Tharakaraman K, Raman R, Raguram S, Shriver Z, Sasisekharan V, Sasisekharan R. Extrapolating from sequence--the 2009 H1N1 'swine' influenza virus. Nat Biotechnol. 2009 Jun;27(6):510-3. PubMed PMID: 19513050.
  • Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009 Jul 24;325(5939):484-7. Epub 2009 Jul 2. PubMed PMID: 19574347.
  • Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1651-6. PubMed PMID: 9990079; PubMed Central PMCID: PMC15547.
  • Brownlee GG, Fodor E. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1871-6. PubMed PMID: 11779386; PubMed Central PMCID: PMC1088563.
  • Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009 Dec 17;361(25):2405-13. Epub 2009 Sep 10. PubMed PMID: 19745216.
  • Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009 Apr 10;324(5924):246-51. Epub 2009 Feb 26. PubMed PMID: 19251591; PubMed Central PMCID: PMC2758658.
  • Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar;16(3):265-73. Epub 2009 Feb 22. PubMed PMID: 19234466; PubMed Central PMCID: PMC2692245.
  • Chen Z, Wang W, Zhou H, Suguitan AL Jr, Shambaugh C, Kim L, Zhao J, Kemble G, Jin H. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol. 2010 Jan;84(1):44-51. Epub . PubMed PMID: 19864389; PubMed Central PMCID: PMC2798434.
  • WHO (2009) Public health significance of virus mutation detected in Norway. http://www.who.int/csr/disease/swineflu/notes/briefing_20091120/en/
  • Kilander A, Rykkvin R, Dudman S, Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill. 2010 Mar 4;15(9). pii: 19498. PubMed PMID: 20214869.

Leave a Comment